BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Polioudaki H, Mala A, Gkimprixi E, Papadaki MA, Chantziou A, Tzardi M, Mavroudis D, Agelaki S, Theodoropoulos PA. Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome. Cancers (Basel) 2020;12:E3735. [PMID: 33322610 DOI: 10.3390/cancers12123735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Papadaki MA, Agelaki S. Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer. Cancers 2022;14:1314. [DOI: 10.3390/cancers14051314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jeong S, Lee N, Park MJ, Jeon K, Song W. Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer. Cancers (Basel) 2021;13:5225. [PMID: 34680373 DOI: 10.3390/cancers13205225] [Reference Citation Analysis]
3 Ouyang Y, Liu W, Zhang N, Yang X, Li J, Long S. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Cancer Med 2021;10:7021-39. [PMID: 34423578 DOI: 10.1002/cam4.4236] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Papadaki MA, Monastirioti A, Apostolopoulou CA, Aggouraki D, Papadaki C, Michaelidou K, Vassilakopoulou M, Alexakou K, Mavroudis D, Agelaki S. TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. Cancers (Basel) 2022;14:1053. [PMID: 35205801 DOI: 10.3390/cancers14041053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]